Investors are weighing what a reported gradual rollout of Trump tariff hikes could mean for inflation and the Fed.

Investors are weighing what a reported gradual rollout of Trump tariff hikes could mean for inflation and the Fed.

Cool wholesale inflation numbers provide only slight relief before Wednesday's release of December Consumer Price Index data.

It matters who gets them." The fine print on the latest ad reads, “Zepbound is not for cosmetic weight loss.” Glaser was right. Ozempic was the frontrunner of online conversations during and ...

About 140,400 obese patients in Massachusetts were prescribed medications like Wegovy and Zepbound in 2024, a 255 percent ...

Biopharma executives shared their thoughts on the potential impacts of the new administration; Annalee Armstrong recaps JPM ...

The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for ... [+] health insurers, employers and government health programs who cover it in 2025.

The U.S. Food and Drug Administration (FDA) has granted approval for Zepbound, a weight-loss medication, to treat moderate to severe obstructive sleep apnea (OSA) in individuals with obesity.

Since Zepbound was approved by the FDA to treat obesity in late 2023, its maker Eli Lilly has been steadily closing in on fierce rival Novo Nordisk’s early lead in the obesity market.

Following positive results from its SURMOUNT-5 trial, Eli Lilly’s Zepbound (tirzepatide) will surpass Novo Nordisk’s Weogvy (semaglutide) in the obesity treatment market, according to a ...